IRL752 displayed its highest in vitro affinities for 5-HT and NA-related targets[2].

IRL752 (3.7-100 μmol/kg, s.c.) has no significant effect on acute hyper-dopaminergic or hypo-glutamatergic motor responses, but reversed deficits resulting from hypomonoaminergic function[2]. Animal Model: Normal rats[2]. Dosage: 3.7-100 μmol/kg. Administration: s.c., 30 min prior to testing. Result: Induced dose-dependent and regio-selective alterations in brain monoamine transmission indices and gene expression.